NRx Pharmaceuticals (NRXP) was upgraded by Zacks Research from "strong sell" to "hold".
NRx Pharmaceuticals (NRXP) had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer [Yahoo! Finance]
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.